194 related articles for article (PubMed ID: 28885866)
21. An updated patent review of calpain inhibitors (2012 - 2014).
Donkor IO
Expert Opin Ther Pat; 2015 Jan; 25(1):17-31. PubMed ID: 25399719
[TBL] [Abstract][Full Text] [Related]
22. A patent review of immunoproteasome inhibitors.
Ogorevc E; Schiffrer ES; Sosič I; Gobec S
Expert Opin Ther Pat; 2018 Jul; 28(7):517-540. PubMed ID: 29865878
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitors closer to market launch?
Galons H; Oumata N; Gloulou O; Meijer L
Expert Opin Ther Pat; 2013 Aug; 23(8):945-63. PubMed ID: 23600454
[TBL] [Abstract][Full Text] [Related]
24. Carboxylate isosteres for caspase inhibitors: the acylsulfonamide case revisited.
Adriaenssens Y; Jiménez Fernández D; Vande Walle L; Elvas F; Joossens J; Lambeir A; Augustyns K; Lamkanfi M; Van der Veken P
Org Biomol Chem; 2017 Sep; 15(35):7456-7473. PubMed ID: 28837200
[TBL] [Abstract][Full Text] [Related]
25. Polymeric networks for controlled release of drugs: a patent review.
du Toit LC; Choonara YE; Kumar P; Pillay V
Expert Opin Ther Pat; 2016 Jun; 26(6):703-17. PubMed ID: 27079971
[TBL] [Abstract][Full Text] [Related]
26. Nitric oxide synthase inhibitors: a review of patents from 2011 to the present.
Yang Y; Yu T; Lian YJ; Ma R; Yang S; Cho JY
Expert Opin Ther Pat; 2015 Jan; 25(1):49-68. PubMed ID: 25380586
[TBL] [Abstract][Full Text] [Related]
27. Nuclear factor-kappa B inhibitors; a patent review (2006-2010).
Kwak JH; Jung JK; Lee H
Expert Opin Ther Pat; 2011 Dec; 21(12):1897-910. PubMed ID: 22098320
[TBL] [Abstract][Full Text] [Related]
28. Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases.
Kent CR; Bryja M; Gustafson HA; Kawarski MY; Lenti G; Pierce EN; Knopp RC; Ceja V; Pati B; Walters DE; Karver CE
Bioorg Med Chem Lett; 2016 Nov; 26(22):5476-5480. PubMed ID: 27777011
[TBL] [Abstract][Full Text] [Related]
29. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Nguyen TL; Fruit C; Hérault Y; Meijer L; Besson T
Expert Opin Ther Pat; 2017 Nov; 27(11):1183-1199. PubMed ID: 28766366
[TBL] [Abstract][Full Text] [Related]
30. Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors.
Musumeci F; Sanna M; Greco C; Giacchello I; Fallacara AL; Amato R; Schenone S
Expert Opin Ther Pat; 2017 Dec; 27(12):1305-1318. PubMed ID: 28705083
[TBL] [Abstract][Full Text] [Related]
31. Peptide Agonists and Antagonists with Potential Application in Neurological Disorders.
Russo A; La Manna S; Morelli G; Novellino E; Marasco D
Recent Pat CNS Drug Discov; 2016; 10(2):76-89. PubMed ID: 27108811
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibition of initiator versus executioner caspases using small peptides containing unnatural amino acids.
Vickers CJ; González-Páez GE; Litwin KM; Umotoy JC; Coutsias EA; Wolan DW
ACS Chem Biol; 2014 Oct; 9(10):2194-8. PubMed ID: 25079698
[TBL] [Abstract][Full Text] [Related]
33. Improved brain uptake of peptide-based CNS drugs via alternative routes of administrations of its nanocarrier delivery systems: a promising strategy for CNS targeting delivery of peptides.
Qian S; Wang Q; Zuo Z
Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1491-508. PubMed ID: 25196358
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic contact lenses: a patent review.
Dixon P; Shafor C; Gause S; Hsu KH; Powell KC; Chauhan A
Expert Opin Ther Pat; 2015; 25(10):1117-29. PubMed ID: 26143943
[TBL] [Abstract][Full Text] [Related]
35. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
Liu G
Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
[TBL] [Abstract][Full Text] [Related]
36. Intranasal Delivery of a Caspase-1 Inhibitor in the Treatment of Global Cerebral Ischemia.
Zhao N; Zhuo X; Lu Y; Dong Y; Ahmed ME; Tucker D; Scott EL; Zhang Q
Mol Neurobiol; 2017 Sep; 54(7):4936-4952. PubMed ID: 27520275
[TBL] [Abstract][Full Text] [Related]
37. The Role of Caspase Family in Acute Brain Injury: The Potential Therapeutic Targets in the Future.
Zhang A; Zhang Z; Liu Y; Lenahan C; Xu H; Jiang J; Yuan L; Wang L; Xu Y; Chen S; Fang Y; Zhang J
Curr Neuropharmacol; 2022; 20(6):1194-1211. PubMed ID: 34766893
[TBL] [Abstract][Full Text] [Related]
38. Caspase Inhibition Prevents Tumor Necrosis Factor-α-Induced Apoptosis and Promotes Necrotic Cell Death in Mouse Hepatocytes in Vivo and in Vitro.
Ni HM; McGill MR; Chao X; Woolbright BL; Jaeschke H; Ding WX
Am J Pathol; 2016 Oct; 186(10):2623-36. PubMed ID: 27616656
[TBL] [Abstract][Full Text] [Related]
39. Emerging delivery platforms for mucosal administration of biopharmaceuticals: a critical update on nasal, pulmonary and oral routes.
Thwala LN; Préat V; Csaba NS
Expert Opin Drug Deliv; 2017 Jan; 14(1):23-36. PubMed ID: 27351299
[TBL] [Abstract][Full Text] [Related]
40. Bcr-Abl tyrosine kinase inhibitors: a patent review.
Desogus A; Schenone S; Brullo C; Tintori C; Musumeci F
Expert Opin Ther Pat; 2015 Apr; 25(4):397-412. PubMed ID: 25656651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
